Skip to main
  1. Stocks
  2. Humana
  3. Forecast
HUM

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 15%
Buy 45%
Hold 35%
Sell 0%
Strong Sell 5%

Bulls say

Humana is well positioned because 3Q26 showed a 30c EPS beat, a 93.7% Insurance benefit ratio versus 94.3% expected, and management raised 2026 adjusted EPS guidance to at least $9.50 as medical cost trends held at the low end of the prior 7-8% range. The company’s core Medicare Advantage franchise is improving on stronger enrollment, retention, and pricing discipline, while individual MA margins are expected to materially expand in 2027 and reach about 3.2% in 2028, supported by improved Stars scores. Meanwhile, CenterWell membership is up about 30%, the balance sheet is strengthening with debt-to-cap falling to 40.9%, and the new JV structure adds capital flexibility and optionality.

Bears say

Humana is facing a deteriorating Medicare Advantage margin recovery story, with normalized margins potentially pushed beyond 2028 and low visibility into near-term medical-loss-ratio improvement as deferred care trends remain uncertain. Competitive pressure is intensifying as legacy and emerging insurers target MA growth, while legislative and reimbursement risks around benchmark cuts, coding intensity adjustments, and home visit coding could further compress rates. The outlook is also weakened by a roughly (3.0%) Group MA Stars headwind in CY26 and estimated Group MA margins of only ~(4.0%) in CY26, even before Medicaid redetermination and exchange-subsidy pressures.

Humana (HUM) has been analyzed by 20 analysts, with a consensus rating of Buy. 15% of analysts recommend a Strong Buy, 45% recommend Buy, 35% suggest Holding, 0% advise Selling, and 5% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Humana (HUM) Analyst Forecast & Price Prediction

Get the latest Humana (HUM) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Humana (HUM)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Buy based on their latest research and market trends.

According to 20 analysts, Humana (HUM) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $466.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $466.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Humana (HUM) Analyst Forecast & Price Prediction

Get the latest Humana (HUM) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Humana (HUM)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover HUM stock data and trends